Liver Cancer Trial, Recruiting (NCT07657897)

Liver Cancer Trial, Recruiting NCT07657897 Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07657897 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have liver cancer (hepatocellular carcinoma) that is suitable for treatment with a procedure called radiofrequency ablation (RFA), which uses heat to destroy cancer cells
People whose tumor is no larger than 3 cm (about the size of a grape) across
People who have been assessed as having an overall health status that falls within a certain accepted range for medical procedures (confirm with trial site)

Who may not be able to join:

People whose cancer is able to be treated with surgery
People who take long-term medications that suppress the immune system
People who have a medical reason why they cannot take any of the medications used in this study
People who have a psychiatric (mental health) disorder
People who have a condition where the immune system attacks the body (an autoimmune disorder)
People who have asthma that requires ongoing steroid medication to control
People who have a blood clotting disorder, whether they were born with it or developed it
People who are HIV-positive
People who are pregnant
People who are on medication to treat an irregular heartbeat

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07657897

Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy

Phase: Not Applicable

Status: Recruiting

Condition: Liver Cancer

More information: https://clinicaltrials.gov/study/NCT07657897

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have liver cancer (hepatocellular carcinoma) that is suitable for treatment with a procedure called radiofrequency ablation (RFA), which uses heat to destroy cancer cells
People whose tumor is no larger than 3 cm (about the size of a grape) across
People who have been assessed as having an overall health status that falls within a certain accepted range for medical procedures (confirm with trial site)

Who may not be able to join:

People whose cancer is able to be treated with surgery
People who take long-term medications that suppress the immune system
People who have a medical reason why they cannot take any of the medications used in this study
People who have a psychiatric (mental health) disorder
People who have a condition where the immune system attacks the body (an autoimmune disorder)
People who have asthma that requires ongoing steroid medication to control
People who have a blood clotting disorder, whether they were born with it or developed it
People who are HIV-positive
People who are pregnant
People who are on medication to treat an irregular heartbeat

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Iuliu Hatieganu University of Medicine and Pharmacy

Registry

ClinicalTrials.gov

Start date

12 November 2024

Est. completion

31 March 2026

Where this trial is recruiting

🇷🇴 Romania

Primary endpoints

Change in Serum Citrullinated Histone H3 (H3Cit) Concentration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov